Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 64, Issue 1, Pages 209-223
Publisher
Wiley
Online
2015-12-29
DOI
10.1002/hep.28432
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hyaluronic acid–tumor necrosis factor-related apoptosis-inducing ligand conjugate for targeted treatment of liver fibrosis
- (2015) Jeong-A Yang et al. Acta Biomaterialia
- Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
- (2015) Kyriakos P. Papadopoulos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- What is the future of PEGylated therapies?
- (2015) Magdalena Swierczewska et al. EXPERT OPINION ON EMERGING DRUGS
- Hepatic inflammation and fibrosis: Functional links and key pathways
- (2015) Ekihiro Seki et al. HEPATOLOGY
- Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
- (2015) Pradeep M. Nair et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Hepatic stellate cells in liver development, regeneration, and cancer
- (2013) Chunyue Yin et al. JOURNAL OF CLINICAL INVESTIGATION
- Evolving therapies for liver fibrosis
- (2013) Detlef Schuppan et al. JOURNAL OF CLINICAL INVESTIGATION
- Therapy for Fibrotic Diseases: Nearing the Starting Line
- (2013) S. L. Friedman et al. Science Translational Medicine
- TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies
- (2012) C. T. Hellwig et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of fibrosis: therapeutic translation for fibrotic disease
- (2012) Thomas A Wynn et al. NATURE MEDICINE
- PEGylated TNF-Related Apoptosis-Inducing Ligand (TRAIL) Analogues: Pharmacokinetics and Antitumor Effects
- (2011) Tae Hyung Kim et al. BIOCONJUGATE CHEMISTRY
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Alcoholic liver disease: pathogenesis and new targets for therapy
- (2011) José Altamirano et al. Nature Reviews Gastroenterology & Hepatology
- TRAIL-mediated signaling in prostate, bladder and renal cancer
- (2011) Christina Voelkel-Johnson Nature Reviews Urology
- FDA-approved poly(ethylene glycol)–protein conjugate drugs
- (2011) Steevens N. S. Alconcel et al. Polymer Chemistry
- Improved Antitumor Activity and Tumor Targeting of NH2-Terminal-Specific PEGylated Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
- (2010) S. Y. Chae et al. MOLECULAR CANCER THERAPEUTICS
- Evolving challenges in hepatic fibrosis
- (2010) Scott L. Friedman Nature Reviews Gastroenterology & Hepatology
- Molecular mechanisms of necroptosis: an ordered cellular explosion
- (2010) Peter Vandenabeele et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Emerging PEGylated drugs
- (2009) Jung Seok Kang et al. EXPERT OPINION ON EMERGING DRUGS
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search